Filed under: Analyst reports, Analyst upgrades and downgrades, Dell (DELL), Chubb Corp (CB), Analyst initiations, Akamai Technologies (AKAM), Marvell Technology Group (MRVL)
Analyst upgrades:
- Citigroup upgraded shares of Akamai (NASDAQ: AKAM) to Buy from Hold following the company's Q4 results as they believe fundamentals are stabilizing. The firm raised their target price to $22 from $12.
- Baird upgraded Theravance (NASDAQ: THRX) to Outperform from Neutral. The firm said the company looks poised to realize the two-product success necessary to drive profitability, and Horizon will likely play a role in succeeding $7B+ Advair. Note that last night Theravance/Glaxo (GSK) reported positive results for Horizon.
- RBC Capital said Aeterna Zentaris (NASDAQ: AEZS) is on the cusp of a Cetrorelix deal and has turned more positive on shares. Shares were upgraded to Outperform from Sector Perform.
- Marvell Tech (NASDAQ: MRVL) was upgraded to Buy from Neutral at Goldman and added to the firm's Conviction Buy List.
- Sangamo BioSciences (NASDAQ: SGMO) was raised to Buy from Neutral at Merriman.
- Arthur J. Gallagher (NYSE: AJG) was upgraded at Piper Jaffray to Buy from Neutral.
Continue reading Analyst upgrades, downgrades and initiations: AKAM, MRVL, THRX, DELL, CRNT, TRV, AEIS ...
Analyst upgrades, downgrades and initiations: AKAM, MRVL, THRX, DELL, CRNT, TRV, AEIS ... originally appeared on BloggingStocks on Thu, 05 Feb 2009 11:45:00 EST. Please see our terms for use of feeds.
Permalink | Email this | Comments